| (210) | Number of the EPO application | 21159353 |
| (220) | Filing date of the EPO application | 2021.02.25 |
| (80) | EPO patent specification publication (B) | EPB nr. 24/2023, 2023.06.14 |
| (110) | EPO patent number | 3872091 |
| (21) | Number of the application | e 2022 0399 |
| (71) | Name(s) of applicant(s), code of the country | VIR Biotechnology, Inc., US; |
| (72) | Name(s) of inventor(s), code of the country | LEMPP Florian A., US;
TELENTI Amalio, US;
CORTI Davide, CH;
FINK Katja, CH;
BELTRAMELLO Martina, CH;
CAMERONI Elisabetta, CH;
PINTO Dora, CH;
SNELL Gyorgy, US; |
| (73) | Name(s) of owner(s), code of the country | VIR Biotechnology, Inc., US; |
| (54) | Title of the invention | ANTIBODIES AGAINST SARS-COV-2 |
| (13) | Kind-of-document code | A1 |
| (51) | International Patent Classification | C07K 16/10 (2006.01.01); A61K 39/395 (2006.01.01); A61P 31/14 (2006.01.01) |
| (19) | Country | US |
| (41) | Date of publication of the application | 2022.05.31 |
| (30) | Priority | 202062981984 P, 2020.02.26, US; 202062982661 P, 2020.02.27, US; 202062987298 P, 2020.03.09, US; 202062989522 P, 2020.03.13, US; 202062990369 P, 2020.03.16, US; 202062992082 P, 2020.03.19, US; 202062994235 P, 2020.03.24, US; 202063001204 P, 2020.03.27, US; 202063003214 P, 2020.03.31, US; 202063005206 P, 2020.04.03, US; 202063010589 P, 2020.04.15, US; 202063011971 P, 2020.04.17, US; 202063014024 P, 2020.04.22, US; 202063023788 P, 2020.05.12, US; 202063025133 P, 2020.05.14, US; 202063039813 P, 2020.06.16, US; 202063043653 P, 2020.06.24, US; 202063050331 P, 2020.07.10, US; 202063052810 P, 2020.07.16, US |